Federated Hermes, Inc. Neoleukin Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.68 - $0.91 $236 - $316	-348 Reduced 18.29%	1,555 $1,000
Q1 2023 May 08, 2023	SELL	$0.5 - $0.72 $1,302 - $1,874	-2,604 Reduced 57.78%	1,903 $1,000
Q4 2022 Feb 13, 2023	BUY	$0.4 - $0.55 $82 - $113	207 Added 4.81%	4,507 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.69 - $1.33 $58 - $113	85 Added 2.02%	4,300 $3,000
Q2 2022 Aug 15, 2022	BUY	$0.92 - $2.25 $1,706 - $4,173	1,855 Added 78.6%	4,215 $4,000
Q1 2022 May 13, 2022	SELL	$1.72 - $5.23 $40,225 - $122,314	-23,387 Reduced 90.83%	2,360 $4,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $119,723 - $199,539	25,747 New	25,747 $124,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.